Profilo
Kenneth A. Bauer has been a Director of GTC Biotherapeutics, Inc. since December 2004, Director of Thrombosis Clinical Research for the Beth Israel Deaconess Medical Center since 1997 and Professor of Medicine at the Harvard Medical School since 2004.
Dr. Bauer has been a Faculty Member of the Harvard Medical School since 1982.
He is Chairman of Council for the International Society on Thrombosis and Haemostasis.
He received a BS and an MS from the Massachusetts Institute of Technology and his Medical Education from the Stanford University School of Medicine.
He completed subspecialty training in medical oncology and hematology at the Dana Farber Cancer Institute and Beth Israel Hospital in Boston.
Posizioni attive di Kenneth A. Bauer
| Società | Posizione | Inizio |
|---|---|---|
The International Society of Thrombosis & Hemostasis | Corporate Officer/Principal | - |
Precedenti posizioni note di Kenneth A. Bauer
| Società | Posizione | Fine |
|---|---|---|
| REVO BIOLOGICS INC | Direttore/Membro del Consiglio | 01/10/2009 |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Corporate Officer/Principal | - |
Formazione di Kenneth A. Bauer
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Health Services |
The International Society of Thrombosis & Hemostasis | |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions | Health Technology |
















